Discovery of Voreloxin as a Dual‐Selective Stabilizer for c‐Myc/Bcl‐2 G‐Quadruplexes in Leukemia
Chemical Biology & Drug Design · 2024
DOI: 10.1111/cbdd.70034 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemical Biology & Drug Design, 2024. Verfasst von Jiacheng Yin und 6 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, Jiangsu, P. R. China. Hauptthemen laut MEDLINE: G-Quadruplexes, Proto-Oncogene Proteins c-bcl-2, Proto-Oncogene Proteins c-myc, Molecular Docking Simulation. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Anhui Provincial Quality Engineering Project, Anhui Training Programs of Innovation and Entrepreneurship for Undergraduates, Anhui Provincial Natural Science Foundation.
Abstract (Originalsprache)
Overexpression of c‐Myc is a key factor in the development of leukemia and other malignancies, highlighting the urgent need for novel drugs to inhibit c‐Myc protein levels. DNA G‐quadruplexes (G4) have emerged as potential regulatory targets for c‐Myc expression. Previous studies identified trovafloxacin, a topoisomerase II inhibitor, as a novel c‐Myc G4 stabilizer. In this study, virtual screening based on structural similarity led to the identification of nine derivatives of trovafloxacin, among which voreloxin exhibited potent cytotoxicity in multiple myeloma cells and showed promising therapeutic efficacy in leukemia cells. FRET assays demonstrated that voreloxin specifically stabilized the G4 structures of c‐Myc and Bcl‐2, with minimal effects on the G4 structures of other oncogenes. Moreover, voreloxin significantly reduced the expression levels of c‐Myc and Bcl‐2 in THP‐1 and MOLM‐13 cells. Molecular docking, molecular dynamics (MD) simulations, and MM/GBSA calculations further confirmed the stable binding of voreloxin to both c‐Myc and Bcl‐2 G4s, primarily driven by π‐π stacking and hydrogen bonding interactions. These findings provide valuable insights for the development of G4‐targeting drugs for cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, Jiangsu, P. R. China.
- School of Medicine, Anhui University of Science and Technology, Huainan, China.
ORCID-Profile: Jian Gao
Förderung
- Anhui Provincial Quality Engineering Project
- Anhui Training Programs of Innovation and Entrepreneurship for Undergraduates
- Anhui Provincial Natural Science Foundation
- Scientific Research Foundation for High-level Talents of Anhui University of Science and Technology
- Natural Science Research Project of Anhui Educational Committee
- Natural Science Foundation of Anhui Province
Zitieren
APA
Yin, J., Jia, P., Qu, X., Han, Z., Yao, L., Wang, S., & Gao, J. (2024). Discovery of Voreloxin as a Dual‐Selective Stabilizer for c‐Myc/Bcl‐2 G‐Quadruplexes in Leukemia. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.70034
Vancouver
Yin J, Jia P, Qu X, Han Z, Yao L, Wang S, et al. Discovery of Voreloxin as a Dual‐Selective Stabilizer for c‐Myc/Bcl‐2 G‐Quadruplexes in Leukemia. Chemical Biology & Drug Design. 2024. doi:10.1111/cbdd.70034
BibTeX
@article{Yin2024,
author = {Yin, Jiacheng and Jia, Pingting and Qu, Xinxin and Han, Zheng and Yao, Longsheng and Wang, Shangzhao and Gao, Jian},
title = {Discovery of Voreloxin as a Dual‐Selective Stabilizer for c‐Myc/Bcl‐2 G‐Quadruplexes in Leukemia},
journal = {Chemical Biology & Drug Design},
year = {2024},
doi = {10.1111/cbdd.70034}
}
EUVIMED